The therapeutic targets for psoriasis are diverse and include the utilization of anti-tumor necrosis factor-alpha (TNF-α) antibodies, anti-interleukin (IL)-12/23p40 antibodies, and anti-IL-17 antibodies. Here, TNF is linked to psoriasis.